By: Matthew Strong, Taiwan News, Staff Writer
TAIPEI (Taiwan News) – President-elect Tsai Ing-wen will resolve possible conflicts of interest due to her brother’s investments in the biotechnology sector before her inauguration on May 20, the Democratic Progressive Party said Saturday.
At a meeting with biotech business leaders recently, Tsai praised the sector’s efforts, including a reportedly failed attempt by OBI Pharma Inc. to develop a working breast cancer drug.
However, a letter to the media alleged Saturday that a brother of Tsai, Tsai Ying-yang, was a board member of the fifth-largest shareholder in OBI Pharma. The shareholding company was even originally named after Tsai’s father and had also played a role in the formation of other biotech firms, reports said. [FULL STORY]